Storia in 3 fonti

Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.

Raccontata da

morningstar.com

statnews.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer's $43B Seagen acquisition shows cracks as sigvotatug vedotin fails to replace docetaxel in lung cancer trials. The failure highlights M&A execution risk, revealing how integration challenges can erode clinical pipelines and shareholder confidence in acquisition-driven growth.

originale

benzinga.com1 mese fa

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.

Leggi questa versione →

Closely watched Pfizer lung cancer drug falls short in clinical trial

Confronto fonti

Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:

Timeline cronologica

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous…

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE: